Replacing Excessive Use of Antibiotics and Antimicrobials
Mechanism of Action
Replicon Health is a Finnish development and commercialization company focusing on reducing acute and chronic inflammation and microbial infections. Our novel patent pending technology is based on several simultaneous enhancements of mitochondrial energy metabolism creating strong and sustained efficacy. Our molecule family (RH activators) can enhance fundamental pathways related to aerobic energy metabolism, ROS scavenging, inflammation control, and even activating of the immune defences. We aim at fast market entry with carefully selected medical and/or nutraceutical solution. Importantly, also our production technology is environmentally sustainable.
Our innovation is based on reduced econometric modelling of ultra-complicated biological systems. With created low cost and high return strategy we have already been able to show in vivo product efficacy in multiple tests with high statistical certainty. Our patented molecule formulation can uniquely influence the causes of many diseases and disorders, not just alleviate the symptoms. Our total potential market is in excess of ten billion USD and feasible sales potential in selected markets is clearly above 100 million USD annually.
10/2018 Replicon Health Oy has filed its first commercialization application. The proprietary new chemical entity can replace excessive use of antimicrobials. It has already been in limited commercial use in the EU area with successful outcomes.
09/2018 Confirmatory knowledge on health benefitting mitochondrial signalling revealed by GC-MS measurements.
08/2018 IPRs moving successfully in selected major market areas
07/2018 Replicon receives the major part of the R&D financing granted in 06/2017 by Business Finland (see below)
05/2018 Small bridge financing from current owners completed (at par value compared to previous round)
04/2018 Successful production related R&D project completed.
03/2018 Tissue / cell level protection against a specific viral infection shown in an in vitro study. (More influential / relevant systemic efficacy against viral infections indicated earlier in several in vivo studies.)
01/2018 New in vitro study confirms the activation of mitochondrial energy metabolism by RH activators in a new tissue type. The study was conducted by an independent university research group who used different analyzing technology compared to previous in vitro and in vivo studies with similar, fully consistent findings.
09/2017 Replicon Health moves to new bigger premises in Otaniemi, Espoo to facilitate smooth ramp up for commercialization of first prooducts.
06/2017 Replicon Health receives R&D financing from TEKES, Finnish Funding Agency for Innovation.
05/2017 Experimental challenge study with pathogenic gram-negative bacteria gave notably good and statistically very significant outcome compared to placebo. However, the experimental study set up had to be slightly modified during the study thus deteriorating scientific impact. Nevertheless, practical economic results were even better than expected.
03/2017 Confirmatory double controlled challenge study has reached its main end points. Conducted two latest efficacy studies now confirm that RH -activators can replace antimicrobial agents in practical applications. Both studies were conducted by independent experts and relevant efficacy results deviate statistically significantly from 0-control (placebo group) in both. Additionally, the test set-up was demanding in respect to revealing the efficacy of RH activators in both studies.
01/2017 Double controlled protozoal challenge study conducted in Oct – Nov 2016 has reached its primary end points. Additionally dose responses were consistent in the study thus confirming positive results. Second test has already been initiated.
10/2016 Replicon Health initiates a series of large scale efficacy studies for commercialization.
01/2016 Replicon Health has filed two additional patent applications related to its invention thus extending the already massive coverage of the IPRs and furthermore confirming the proof of concept of the main invention.